10-Q/APeriod: Q2 FY1997

BIOGEN INC. Quarterly Report (Amendment) for Q2 Ended Jun 30, 1997

Filed August 18, 1997For Securities:BIIB

Summary

This amendment to Biogen Inc.'s (BIIB) Form 10-Q for the period ending June 30, 1997, provides an updated filing from August 18, 1997. As this is an amended filing, it suggests a need for correction or additional information beyond the initial submission. Investors should note that this document likely contains revised financial statements or disclosures that are critical for understanding the company's financial health and operational status during the second quarter of 1997. Without the specific financial data and narrative disclosures from the filing itself, a detailed analysis is limited, but the act of amending the report indicates a focus on accuracy and completeness in reporting to shareholders and the SEC. Investors interested in Biogen at this time should pay close attention to any changes in revenue, expenses, net income, and cash flows presented in the amended financials. Additionally, any updated management discussion and analysis (MD&A) or notes to the financial statements could reveal significant operational developments, research and development updates, or changes in business strategy. The amendment process itself underscores the importance of the information being corrected or added, making it a key area for investor scrutiny.

Key Highlights

  • 1Amended 10-Q filing for Biogen Inc. (BIIB) for the period ending June 30, 1997.
  • 2Filed on August 18, 1997, indicating a revision to the original quarterly report.
  • 3Focus on the period of the second quarter of 1997.
  • 4The amendment suggests a need for updated or corrected financial and/or narrative disclosures.
  • 5Crucial for investors seeking the most accurate financial and operational information for the period.
  • 6Investors should review the amended content for any material changes from the initial filing.

Frequently Asked Questions

An amended 10-Q filing (10-Q/A) indicates that Biogen Inc. has corrected or added information to its previously filed quarterly report for the period ending June 30, 1997. This suggests that the original filing may have contained errors, omissions, or required updates, making the amended version the most accurate and complete representation of the company's financial status and operations for that period.

Investors should pay close attention to the revised financial statements, including the consolidated balance sheets, statements of operations, and statements of cash flows. Any changes in key metrics like revenue, cost of goods sold, operating expenses, net income, earnings per share, and cash balances are critical. Additionally, any updated notes to the financial statements could provide further context or detail on accounting policies or significant transactions.

Investors should review the Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A) section for any updated commentary on the company's performance, business trends, and outlook. Any changes in disclosures related to risks, litigation, or significant business developments are also crucial for a comprehensive understanding of Biogen's situation as of June 30, 1997.

The provided text is a directory listing from the SEC's EDGAR database and does not contain the full content of the 10-Q/A filing. To access the complete filing, you would typically search the SEC EDGAR database using the company name (BIOGEN INC.) or ticker symbol (BIIB) and the filing date (August 18, 1997) or form type (10-Q/A).